Transformation by a nucleotide-activated P2Y receptor is mediated by activation of Gαi, Gαq and Rho-dependent signaling pathways

Journal of Molecular Signaling

Volumn 5, Issue , 2010, Pages

  Singh, Anurag ^a,b   Boyer, José L ^b   Der, Channing J ^a,b   Zohn, Irene E ^a,b,c,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c CHILDREN S RESEARCH INSTITUTE   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVES; RODENTIA;

EID: 77954799284     PISSN: None     EISSN: 17502187     Source Type: Journal    
DOI: 10.1186/1750-2187-5-11     Document Type: Article

References (45)

1. Harden TK, Boyer JL, Nicholas RA. P2-purinergic receptors: subtype-associated signaling responses and structure. Annu Rev Pharmacol Toxicol 1995, 35:541-579. 10.1146/annurev.pa.35.040195.002545, 7598506.
2. Burnstock G, Kennedy C. Is there a basis for distinguishing two types of P2-purinoceptor?. Gen Pharmacol 1985, 16:433-440.
3. Abbracchio MP, Burnstock G, Boeynaems JM, Barnard EA, Boyer JL, Kennedy C, Knight GE, Fumagalli M, Gachet C, Jacobson KA, Weisman GA. International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapy. Pharmacol Rev 2006, 58:281-341. 10.1124/pr.58.3.3, 16968944.
4. White N, Burnstock G. P2 receptors and cancer. Trends Pharmacol Sci 2006, 27:211-217. 10.1016/j.tips.2006.02.004, 16530853.
5. Deli T, Csernoch L. Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors. Pathol Oncol Res 2008, 14:219-231. 10.1007/s12253-008-9071-7, 18575829.
6. Pathak R, Bhatnagar S, Dubey AK. Mechanisms underlying the opposing effects of P2Y receptors on the cell cycle. J Recept Signal Transduct Res 2008, 28:505-529. 10.1080/10799890802539559, 19061072.
7. White N, Ryten M, Clayton E, Butler P, Burnstock G. P2Y purinergic receptors regulate the growth of human melanomas. Cancer Lett 2005, 224:81-91.
8. Popper LD, Batra S. Calcium mobilization and cell proliferation activated by extracellular ATP in human ovarian tumour cells. Cell Calcium 1993, 14:209-218. 10.1016/0143-4160(93)90068-H, 8500137.
9. Katzur AC, Koshimizu T, Tomic M, Schultze-Mosgau A, Ortmann O, Stojilkovic SS. Expression and responsiveness of P2Y2 receptors in human endometrial cancer cell lines. J Clin Endocrinol Metab 1999, 84:4085-4091. 10.1210/jc.84.11.4085, 10566654.
10. Dixon CJ, Bowler WB, Fleetwood P, Ginty AF, Gallagher JA, Carron JA. Extracellular nucleotides stimulate proliferation in MCF-7 breast cancer cells via P2-purinoceptors. Br J Cancer 1997, 75:34-39. 2222689, 9000595.
11. Schafer R, Sedehizade F, Welte T, Reiser G. ATP- and UTP-activated P2Y receptors differently regulate proliferation of human lung epithelial tumor cells. Am J Physiol Lung Cell Mol Physiol 2003, 285:L376-385.
12. Hatanaka H, Takada S, Choi YL, Fujiwara S, Soda M, Enomoto M, Kurashina K, Watanabe H, Yamashita Y, Sugano K, Mano H. Transforming activity of purinergic receptor P2Y, G-protein coupled, 2 revealed by retroviral expression screening. Biochem Biophys Res Commun 2007, 356:723-726. 10.1016/j.bbrc.2007.03.048, 17382903.
13. Erb L, Liao Z, Seye CI, Weisman GA. P2 receptors: intracellular signaling. Pflugers Arch 2006, 452:552-562. 10.1007/s00424-006-0069-2, 16586093.
14. Bagchi S, Liao Z, Gonzalez FA, Chorna NE, Seye CI, Weisman GA, Erb L. The P2Y2 nucleotide receptor interacts with alphav integrins to activate Go and induce cell migration. J Biol Chem 2005, 280:39050-39057. 10.1074/jbc.M504819200, 16186116.
15. Liao Z, Seye CI, Weisman GA, Erb L. The P2Y2 nucleotide receptor requires interaction with alpha v integrins to access and activate G12. J Cell Sci 2007, 120:1654-1662. 10.1242/jcs.03441, 2713722, 17452627.
16. Whitehead IP, Zohn IE, Der CJ. Rho GTPase-dependent transformation by G protein-coupled receptors. Oncogene 2001, 20:1547-1555. 10.1038/sj.onc.1204188, 11313901.
17. Wennerberg K, Der CJ. Rho-family GTPases: it's not only Rac and Rho (and I like it). J Cell Sci 2004, 117:1301-1312. 10.1242/jcs.01118, 15020670.
18. Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene 1998, 17:1415-1438. 10.1038/sj.onc.1202181, 9779988.
19. Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005, 21:247-269. 10.1146/annurev.cellbio.21.020604.150721, 16212495.
20. Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol 2005, 6:167-180. 10.1038/nrm1587, 15688002.
21. Zohn IE, Symons M, Chrzanowska-Wodnicka M, Westwick JK, Der CJ. Mas oncogene signaling and transformation require the small GTP-binding protein Rac. Mol Cell Biol 1998, 18:1225-1235. 108835, 9488437.
22. Zohn IE, Klinger M, Karp X, Kirk H, Symons M, Chrzanowska-Wodnicka M, Der CJ, Kay RJ. G2A is an oncogenic G protein-coupled receptor. Oncogene 2000, 19:3866-3877. 10.1038/sj.onc.1203731, 10951580.
23. Martin CB, Mahon GM, Klinger MB, Kay RJ, Symons M, Der CJ, Whitehead IP. The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene 2001, 20:1953-1963. 10.1038/sj.onc.1204281, 11360179.
24. Fromm C, Coso OA, Montaner S, Xu N, Gutkind JS. The small GTP-binding protein Rho links G protein-coupled receptors and Galpha12 to the serum response element and to cellular transformation. Proc Natl Acad Sci USA 1997, 94:10098-10103. 10.1073/pnas.94.19.10098, 23316, 9294169.
25. Boyer JL, Waldo GL, Harden TK. Molecular cloning and expression of an avian G protein-coupled P2Y receptor. Mol Pharmacol 1997, 52:928-934.
26. Boyer JL, Delaney SM, Villanueva D, Harden TK. A molecularly identified P2Y receptor simultaneously activates phospholipase C and inhibits adenylyl cyclase and is nonselectively activated by all nucleoside triphosphates. Mol Pharmacol 2000, 57:805-810.
27. Solski PA, Abe K, Der CJ. Analyses of transforming activity of Rho family activators. Methods Enzymol 2000, 325:425-441. full_text, 11036624.
28. Khosravi-Far R, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Rac1, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 1995, 15:6443-6453. 230895, 7565796.
29. Qiu RG, Abo A, McCormick F, Symons M. Cdc42 regulates anchorage-independent growth and is necessary for Ras transformation. Mol Cell Biol 1997, 17:3449-3458. 232198, 9154844.
30. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature 1995, 374:457-459. 10.1038/374457a0, 7700355.
31. Khosravi-Far R, Chrzanowska-Wodnicka M, Solski PA, Eva A, Burridge K, Der CJ. Dbl and Vav mediate transformation via mitogen-activated protein kinase pathways that are distinct from those activated by oncogenic Ras. Mol Cell Biol 1994, 14:6848-6857. 359215, 7935402.
32. Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, Van Aelst L, Wigler MH, Der CJ. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 1996, 16:3923-3933. 231389, 8668210.
33. Hooley R, Yu CY, Symons M, Barber DL. G alpha 13 stimulates Na+-H+ exchange through distinct Cdc42-dependent and RhoA-dependent pathways. J Biol Chem 1996, 271:6152-6158. 10.1074/jbc.271.11.6152, 8626403.
34. Buhl AM, Johnson NL, Dhanasekaran N, Johnson GL. G alpha 12 and G alpha 13 stimulate Rho-dependent stress fiber formation and focal adhesion assembly. J Biol Chem 1995, 270:24631-24634. 10.1074/jbc.270.42.24631, 7559569.
35. Gupta SK, Gallego C, Lowndes JM, Pleiman CM, Sable C, Eisfelder BJ, Johnson GL. Analysis of the fibroblast transformation potential of GTPase-deficient gip2 oncogenes. Mol Cell Biol 1992, 12:190-197. 364083, 1729598.
36. Kalinec G, Nazarali AJ, Hermouet S, Xu N, Gutkind JS. Mutated alpha subunit of the Gq protein induces malignant transformation in NIH 3T3 cells. Mol Cell Biol 1992, 12:4687-4693. 360395, 1328859.
37. Althoefer H, Eversole-Cire P, Simon MI. Constitutively active Galphaq and Galpha13 trigger apoptosis through different pathways. J Biol Chem 1997, 272:24380-24386. 10.1074/jbc.272.39.24380, 9305896.
38. Westwick JK, Lambert QT, Clark GJ, Symons M, Van Aelst L, Pestell RG, Der CJ. Rac regulation of transformation, gene expression, and actin organization by multiple, PAK-independent pathways. Mol Cell Biol 1997, 17:1324-1335. 231857, 9032259.
39. Woon CW, Soparkar S, Heasley L, Johnson GL. Expression of a G alpha s/G alpha i chimera that constitutively activates cyclic AMP synthesis. J Biol Chem 1989, 264:5687-5693.
40. Clark GJ, Cox AD, Graham SM, Der CJ. Biological assays for Ras transformation. Methods Enzymol 1995, 255:395-412. full_text, 8524126.
41. Cox AD, Der CJ. Biological assays for cellular transformation. Methods Enzymol 1994, 238:277-294. full_text, 7799794.
42. Karnoub AE, Worthylake DK, Rossman KL, Pruitt WM, Campbell SL, Sondek J, Der CJ. Molecular basis for Rac1 recognition by guanine nucleotide exchange factors. Nat Struct Biol 2001, 8:1037-1041. 10.1038/nsb719, 11685227.
43. Mitin N, Betts L, Yohe ME, Der CJ, Sondek J, Rossman KL. Release of autoinhibition of ASEF by APC leads to CDC42 activation and tumor suppression. Nat Struct Mol Biol 2007, 14:814-823. 10.1038/nsmb1290, 2716141, 17704816.
44. Lambert JM, Lambert QT, Reuther GW, Malliri A, Siderovski DP, Sondek J, Collard JG, Der CJ. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol 2002, 4:621-625.
45. Solski PA, Wilder RS, Rossman KL, Sondek J, Cox AD, Campbell SL, Der CJ. Requirement for C-terminal sequences in regulation of Ect2 guanine nucleotide exchange specificity and transformation. J Biol Chem 2004, 279:25226-25233. 10.1074/jbc.M313792200, 15073184.